BACKGROUND: Angiosarcomas are rare mesenchymal sarcomas that can present as primary cutaneous or noncutaneous disease. They express a variety of vascular endothelial growth factor receptors. The authors hypothesized that the treatment of angiosarcoma with pazopanib, a multikinase inhibitor with activity against vascular endothelial growth factor receptors, would result in disease response and prolonged disease stabilization. METHODS: This was an open-label, phase 2 trial of pazopanib in patients who had incurable angiosarcoma. The co-primary end points were response according to the Response Evaluation Criteria in Solid Tumors and progression-free survival (PFS) at 3 months. The starting dose of pazopanib was 800 mg daily. RESULTS: Twenty-nine patients were accrued between 2011 and 2018, and 22 patients were evaluable for response. Toxicities were similar to those identified in prior reports. There was one partial response (3%), and the clinical benefit rate (including complete responses, partial responses, and stable disease) was 48%, which was observed more frequently in patients who had cutaneous disease. The median PFS was 14.4 weeks, and the 3-month PFS rate determined by Kaplan-Meier estimate was 54.6% (95% CI, 36.0%-82.9%), meeting the primary study objective. The Kaplan-Meier overall survival estimate was 16.1 months. CONCLUSIONS: Pazopanib therapy in patients who had incurable angiosarcoma was associated with meaningful disease control, especially in those who had cutaneous disease with limited objective responses.

Acute myeloid Leukemia (AML)'s incidence increases with age and more than 50% of patients are older than 60 years old. The treatment of AML in this age group population has been drastically changed since 2017 with all new innovative drugs approved by FDA highlighting the fact that "one size fit all" approach is not suitable to treat older patients with AML. However, the treatment of AML in elderly population yet to be defined as choosing the right treatment would depend on several other factors including performance status, comorbidities, along with diversities in leukemia subtype and characteristics (next gene sequencing, cytogenetics). Herein we have tried to focus on this specific age group and describe different treatment options (chemotherapy, immune checkpoint inhibitors, Bispecific T-cell engagers (BiTES), Chimeric Antigen Receptor T-cell Therapies (CAR-T), and Allogeneic Hematopoietic Stem Cell Transplantation) based on the available studies and ongoing clinical trials preliminary results.